Nimbolide Represses the Proliferation, Migration, and Invasion of Bladder Carcinoma Cells Via Chk2-Mediated G2/M Phase Cell Cycle Arrest, Altered Signaling Pathways, and Reduced Transcription Factors-Associated MMP-9 Expression

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2019 Aug 9

PMID 31391858

Citations 10

Authors

Seung-Shick Shin

Byungdoo Hwang

Kashif Muhammad

Yujeong Gho

Jun-Hui Song

Wun-Jae Kim

Gonhyung Kim

Sung-Kwon Moon

Affiliations

Soon will be listed here.

Abstract

Nimbolide, an active chemical constituent of , reportedly has several physiological effects. Here, we assessed novel anticancer effects of nimbolide against bladder cancer EJ and 5637 cells. Nimbolide treatment inhibited the proliferation of both bladder cancer cell lines with an IC value of 3 M. Treatment of cells with nimbolide induced G2/M phase cell cycle arrest via both Chk2-Cdc25C-Cdc2/cyclin B1-Wee1 pathway and Chk2-p21WAF1-Cdc2/cyclin B1-Wee1 pathway. Nimbolide increased JNK phosphorylation and decreased p38MAPK and AKT phosphorylation. Additionally, nimbolide impeded both wound healing migration and invasion abilities by suppressing matrix metalloproteinase-9 (MMP-9) activity. Finally, nimbolide repressed the binding activity of NF-B, Sp-1, and AP-1 motifs, which are key transcription factors for MMP-9 activity regulation. Overall, our study indicates that nimbolide is a potential chemotherapeutic agent for bladder cancer.

Citing Articles

Nimbolide: promising agent for prevention and treatment of chronic diseases (recent update).

Rajendran P, Renu K, Abdallah B, Ali E, Veeraraghavan V, Sivalingam K Food Nutr Res. 2024; 68.

PMID: 38571915 PMC: 10989234. DOI: 10.29219/fnr.v68.9650.

Targeting B4GALT7 suppresses the proliferation, migration and invasion of hepatocellular carcinoma through the Cdc2/CyclinB1 and miR-338-3p/MMP2 pathway.

Liu C, Jia Y, Zhao X, Wang Z, Zhu X, Zhang C PeerJ. 2023; 11:e16450.

PMID: 38025683 PMC: 10668818. DOI: 10.7717/peerj.16450.

Urinary sp. Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway.

Zhang Y, Wang W, Zhou H, Cui Y Cancers (Basel). 2023; 15(3).

PMID: 36765767 PMC: 9913387. DOI: 10.3390/cancers15030809.

Glucosidase inhibitor, Nimbidiol ameliorates renal fibrosis and dysfunction in type-1 diabetes.

Juin S, Pushpakumar S, Tyagi S, Sen U Sci Rep. 2022; 12(1):21707.

PMID: 36522378 PMC: 9755213. DOI: 10.1038/s41598-022-25848-1.

Exploring the therapeutic potential of Neem () for the treatment of prostate cancer: a literature review.

Batra N, Kumar V, Nambiar R, De Souza C, Yuen A, Le U Ann Transl Med. 2022; 10(13):754.

PMID: 35957716 PMC: 9358515. DOI: 10.21037/atm-22-94.

References

Gupta S, Prasad S, Tyagi A, Kunnumakkara A, Aggarwal B . Neem (Azadirachta indica): An indian traditional panacea with modern molecular basis. Phytomedicine. 2017; 34:14-20. DOI: 10.1016/j.phymed.2017.07.001. View

Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T . Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993; 53(22):5365-9. View

Bond M, Fabunmi R, Baker A, Newby A . Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998; 435(1):29-34. DOI: 10.1016/s0014-5793(98)01034-5. View

Gunadharini D, Elumalai P, Arunkumar R, Senthilkumar K, Arunakaran J . Induction of apoptosis and inhibition of PI3K/Akt pathway in PC-3 and LNCaP prostate cancer cells by ethanolic neem leaf extract. J Ethnopharmacol. 2011; 134(3):644-50. DOI: 10.1016/j.jep.2011.01.015. View

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

Kamiyama M, Naguro I, Ichijo H . In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression. Cancer Sci. 2015; 106(7):785-96. PMC: 4520628. DOI: 10.1111/cas.12676. View

Wang L, Phan D, Zhang J, Ong P, Thuya W, Soo R . Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development. Oncotarget. 2016; 7(28):44790-44802. PMC: 5190135. DOI: 10.18632/oncotarget.8316. View

Mayer I, Arteaga C . The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2015; 67:11-28. DOI: 10.1146/annurev-med-062913-051343. View

Subramani R, Gonzalez E, Arumugam A, Nandy S, Gonzalez V, Medel J . Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Sci Rep. 2016; 6:19819. PMC: 4726267. DOI: 10.1038/srep19819. View

10.

Lv T, Wang G . Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins. Exp Ther Med. 2015; 10(1):323-329. PMC: 4487066. DOI: 10.3892/etm.2015.2480. View

11.

Ghagane S, Puranik S, Kumbar V, Nerli R, Jalalpure S, B Hiremath M . antioxidant and anticancer activity of leaf extracts on human prostate cancer cell lines. Integr Med Res. 2017; 6(1):79-87. PMC: 5395687. DOI: 10.1016/j.imr.2017.01.004. View

12.

Vidya Priyadarsini R, Senthil Murugan R, Sripriya P, Karunagaran D, Nagini S . The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells. Free Radic Res. 2010; 44(6):624-34. DOI: 10.3109/10715761003692503. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Sato H, Seiki M . Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 1993; 8(2):395-405. View

15.

Elumalai P, Brindha Mercy A, Arunkamar R, Sharmila G, Bhat F, Balakrishnan S . Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines. Cell Prolif. 2014; 47(6):540-52. PMC: 6495824. DOI: 10.1111/cpr.12148. View

16.

Rundle S, Bradbury A, Drew Y, Curtin N . Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers (Basel). 2017; 9(5). PMC: 5447951. DOI: 10.3390/cancers9050041. View

17.

Zaravinos A, Lambrou G, Volanis D, Delakas D, Spandidos D . Spotlight on differentially expressed genes in urinary bladder cancer. PLoS One. 2011; 6(4):e18255. PMC: 3071699. DOI: 10.1371/journal.pone.0018255. View

18.

Li Y, Li S, Meng X, Gan R, Zhang J, Li H . Dietary Natural Products for Prevention and Treatment of Breast Cancer. Nutrients. 2017; 9(7). PMC: 5537842. DOI: 10.3390/nu9070728. View

19.

Jeggo P, Pearl L, Carr A . DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2015; 16(1):35-42. DOI: 10.1038/nrc.2015.4. View

20.

Bodduluru L, Kasala E, Thota N, Barua C, Sistla R . Chemopreventive and therapeutic effects of nimbolide in cancer: the underlying mechanisms. Toxicol In Vitro. 2014; 28(5):1026-35. DOI: 10.1016/j.tiv.2014.04.011. View